Best Peptides of 2025
2025 represents a landmark year for peptide medicine with Tirzepatide establishing itself as the weight loss leader, next-generation compounds advancing through clinical trials, and increasing scientific understanding of healing and longevity peptides. This annual ranking highlights the most significant peptides across all categories.
Our Ranking Criteria
Rankings
Tirzepatide
Phase 4 (Post-Market)The peptide of 2025. Zepbound established itself as the most effective FDA-approved weight loss medication, with expanding research into MASH, heart failure, and sleep apnea. Supply is finally improving.
Pros
Cons
Semaglutide
Phase 4 (Post-Market)Continues to dominate with SELECT trial cardiovascular data solidifying its position and ongoing research into Alzheimer, MASH, and addiction applications. The broadest therapeutic potential of any peptide.
Pros
Cons
Retatrutide
Phase 3 Clinical TrialsPhase 3 trials advancing for the triple agonist that showed 24-29% weight loss in Phase 2. The most anticipated weight loss compound expected to define the next era if approved.
Pros
Cons
BPC-157
PreclinicalRemains the most popular research peptide in 2025 with continued preclinical publications and growing mainstream awareness. FDA compounding regulations have increased focus on quality and sourcing.
Pros
Cons
GHK-Cu
Clinical (topical) / Preclinical (systemic)Growing recognition in 2025 as gene expression research reveals the breadth of its biological effects. Expanding from skincare niche into longevity research interest.
Pros
Cons
Orforglipron
Phase 3 Clinical TrialsPhase 3 trials advancing for the first true oral GLP-1 therapy without fasting requirements. If approved, it could transform GLP-1 therapy accessibility for millions.
Pros
Cons
FOXO4-DRI
PreclinicalSenolytic peptide research continues to generate excitement in the longevity community. While still preclinical, the concept of selectively clearing senescent cells remains the most compelling aging intervention.
Pros
Cons
Methodology
Annual rankings weigh 2025-specific milestones, clinical developments, regulatory changes, and overall field impact. We balance current clinical utility with forward-looking significance.
Frequently Asked Questions
What was the biggest peptide development in 2025?
Tirzepatide expansion and Retatrutide Phase 3 progress represent the biggest developments. The weight loss peptide field continues to advance rapidly with multiple next-generation compounds in late-stage trials.
Are there any new FDA-approved peptides in 2025?
No new peptide approvals occurred in 2025, but Tirzepatide received expanded indications. Retatrutide and Orforglipron are the nearest to potential approval in upcoming years.
What peptide trends are emerging for 2026?
Key trends include oral GLP-1 therapy development, senolytic peptide research expansion, growing interest in mitochondrial peptides, and increasing regulatory scrutiny on compounded peptides driving quality improvements.